✉ Email this page to a colleague
« Back to Dashboard
Tiglutik Kit is a drug marketed by Italfarmaco Spa and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-five patent family members in twenty-one countries.
The generic ingredient in TIGLUTIK KIT is riluzole. There are nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the riluzole profile page.
A generic version of TIGLUTIK KIT was approved as riluzole by IMPAX LABS on January 29th, 2003.
TIGLUTIK KIT is protected by one US patents.
Patents protecting TIGLUTIK KIT
Riluzole aqueous suspensions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Italfarmaco Spa||TIGLUTIK KIT||riluzole||SUSPENSION;ORAL||209080-001||Sep 5, 2018||RX||Yes||Yes||See Plans and Pricing||See Plans and Pricing||Y||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
See the table below for patents covering TIGLUTIK KIT around the world.
|Country||Patent Number||Title||Estimated Expiration|
|Japan||2012520254||See Plans and Pricing|
|Poland||2405890||See Plans and Pricing|
|Croatia||P20130021||See Plans and Pricing|
|Denmark||2405890||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|